Solid tumors routinely outgrow their blood supply, creating oxygen-starved cores where most therapies lose potency. Understanding the molecular machinery that lets cancer cells not merely survive but actively proliferate under hypoxia has been a long-standing gap — and a potential therapeutic opening. A newly identified lysosomal protein appears to sit squarely at that junction, rewriting assumptions about how calcium and oxygen sensing interact at the subcellular level.
Published in PNAS, the research identifies TMEM165 — a calcium transporter embedded in the lysosomal membrane — as a hypoxia-responsive protein that cancer cells upregulate when oxygen drops. Rather than acting as a passive ion channel, TMEM165 actively redistributes calcium between the lysosome and the cytosol, reshaping intracellular calcium gradients in ways that favor tumor cell survival and proliferation. The work positions TMEM165 as a functional link between lysosomal calcium homeostasis and the broader cellular hypoxia-adaptation program, a connection that had not been mechanistically established before.
Calcium's role as a second messenger in cancer is well recognized, but it has historically been studied at the plasma membrane or endoplasmic reticulum. The lysosome as a calcium signaling hub has gained significant traction only in the past decade, and TMEM165 fits into an emerging picture where lysosomes act as dynamic calcium reservoirs rather than passive degradation chambers. What makes this finding potentially actionable is that TMEM165 appears to be specifically recruited under conditions — hypoxia — that already correlate with treatment resistance and metastatic potential. If its expression or activity can be selectively disrupted, the strategy could sensitize hypoxic tumor zones to existing therapies without broadly perturbing calcium homeostasis in healthy tissue. Limitations worth noting include the current reliance on cell-culture and likely animal models; clinical translation will require validation in patient-derived tumors across multiple cancer types. Still, identifying a druggable transporter at this critical metabolic crossroads qualifies as a meaningful mechanistic advance.